Matthew W. Johnson

Sitert av

	Alle	Siden 2020
Sitater	28542	19073
h-indeks	73	57
i10-indeks	147	128

4700

2350

1175

3525

2006200720082009201020112012201320142015201620172018201920202021202220232024202574 121 153 191 237 270 387 450 509 724 974 1257 1619 1564 2160 3155 4000 4329 4638 706

Offentlig tilgang

Vis alle

118 artikler

5 artikler

tilgjengelige

ikke tilgjengelige

Basert på finansieringsmandater

Medforfattere

Roland R. GriffithsProfessor, Departments of Psychiatry and Neuroscience, Johns Hopkins University School of MedicineVerifisert e-postadresse på jhmi.edu
Patrick S. JohnsonAssociate Professor, California State University, ChicoVerifisert e-postadresse på csuchico.edu
Frederick BarrettMcCabe Professor; Director, Center for Psychedelic & Consciousness Research; Johns Hopkins SOMVerifisert e-postadresse på jhmi.edu
Margaret KlinedinstJohns Hopkins UniversityVerifisert e-postadresse på jhu.edu
Peter S. HendricksProfessor, University of Alabama at Birmingham School of Public HealthVerifisert e-postadresse på uab.edu
Maggie SweeneyNational Institute of Mental Health, National Institutes of HealthVerifisert e-postadresse på nih.gov
Olga RassJohns Hopkins University School of MedicineVerifisert e-postadresse på jhmi.edu
Forest BakerLinkedInVerifisert e-postadresse på linkedin.com
Jeannie-Marie LeoutsakosAssociate Professor of Psychiatry, Johns Hopkins School of MedicineVerifisert e-postadresse på jhu.edu
Eric C. StrainProfessor, Johns Hopkins University School of MedicineVerifisert e-postadresse på jhmi.edu
Ryan VandreyJohns Hopkins UniversityVerifisert e-postadresse på jhmi.edu
Ethan S HurwitzUniversity of California, San DiegoVerifisert e-postadresse på ucsd.edu
Tom PrisinzanoUniversity of KentuckyVerifisert e-postadresse på uky.edu
Lauren PacekRutgers Institute for Nicotine & Tobacco StudiesVerifisert e-postadresse på rutgers.edu
Mikhail KoffarnusUniversity of KentuckyVerifisert e-postadresse på uky.edu
James MacKillopPeter Boris Centre for Addictions Research, McMaster UniversityVerifisert e-postadresse på mcmaster.ca
Gary BadgerBiostatistician, Department of Medical Biostatistics, University of VermontVerifisert e-postadresse på uvm.edu
C. Brendan ClarkWichita State UniversityVerifisert e-postadresse på wichita.edu
Stephen HigginsProfessor of Psychiatry and Psychology, University of VermontVerifisert e-postadresse på uvm.edu
James G. MurphyProfessor and Moss Chair of Excellence in Psychology, University of MemphisVerifisert e-postadresse på memphis.edu

Følg

Matthew W. Johnson

Professor of Psychiatry and Behavioral Sciences, Johns Hopkins University

Verifisert e-postadresse på jhu.edu - Startside

Delay discounting Psychedelics Behavioral Pharmacology Behavior analysis Drug abuse


Tittel Sorter etter sitater Sorter etter år Sorter etter tittel	Sitert av Sitert av	År
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial RR Griffiths, MW Johnson, MA Carducci, A Umbricht, WA Richards, ... Journal of Psychopharmacology 30 (12), 1181-1197, 2016	2318	2016
Human hallucinogen research: guidelines for safety MW Johnson, WA Richards, RR Griffiths Journal of Psychopharmacology 22 (6), 603-620, 2008	1344	2008
Within‐subject comparison of real and hypothetical money rewards in delay discounting MW Johnson, WK Bickel Journal of the experimental analysis of behavior 77 (2), 129-146, 2002	1288	2002
Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial AK Davis, FS Barrett, DG May, MP Cosimano, ND Sepeda, MW Johnson, ... JAMA psychiatry 78 (5), 481-489, 2021	1214	2021
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later RR Griffiths, WA Richards, MW Johnson, UD McCann, R Jesse Journal of psychopharmacology 22 (6), 621-632, 2008	1201	2008
Pilot study of the 5-HT_2AR agonist psilocybin in the treatment of tobacco addiction MW Johnson, A Garcia-Romeu, MP Cosimano, RR Griffiths Journal of Psychopharmacology 28 (11), 983-992, 2014	1116	2014
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects RR Griffiths, MW Johnson, WA Richards, BD Richards, U McCann, ... Psychopharmacology 218, 649-665, 2011	1067	2011
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness KA MacLean, MW Johnson, RR Griffiths Journal of Psychopharmacology 25 (11), 1453-1461, 2011	1045	2011
Delay discounting in current and never-before cigarette smokers: similarities and differences across commodity, sign, and magnitude. F Baker, MW Johnson, WK Bickel Journal of abnormal psychology 112 (3), 382, 2003	789	2003
Long-term follow-up of psilocybin-facilitated smoking cessation MW Johnson, A Garcia-Romeu, RR Griffiths The American journal of drug and alcohol abuse 43 (1), 55-60, 2017	733	2017
The behavioral economics of substance use disorders: reinforcement pathologies and their repair WK Bickel, MW Johnson, MN Koffarnus, J MacKillop, JG Murphy Annual review of clinical psychology 10, 641-677, 2014	705	2014
Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction A Garcia-Romeu, R R Griffiths, M W Johnson Current drug abuse reviews 7 (3), 157-164, 2014	598	2014
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin FS Barrett, MW Johnson, RR Griffiths Journal of Psychopharmacology 29 (11), 1182-1190, 2015	585	2015
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences TM Carbonaro, MP Bradstreet, FS Barrett, KA MacLean, R Jesse, ... Journal of Psychopharmacology 30 (12), 1268-1278, 2016	582	2016
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and … RR Griffiths, MW Johnson, WA Richards, BD Richards, R Jesse, ... Journal of Psychopharmacology 32 (1), 49-69, 2018	576	2018
An algorithm for identifying nonsystematic delay-discounting data. MW Johnson, WK Bickel Experimental and clinical psychopharmacology 16 (3), 264, 2008	566	2008
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function MW Johnson, PS Hendricks, FS Barrett, RR Griffiths Pharmacology & therapeutics 197, 83-102, 2019	530	2019
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population PS Hendricks, CB Thorne, CB Clark, DW Coombs, MW Johnson Journal of Psychopharmacology 29 (3), 280-288, 2015	470	2015
Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin KA MacLean, JMS Leoutsakos, MW Johnson, RR Griffiths Journal for the scientific study of religion 51 (4), 721-737, 2012	456	2012
Psychedelics as medicines: an emerging new paradigm DE Nichols, MW Johnson, CD Nichols Clinical Pharmacology & Therapeutics 101 (2), 209-219, 2017	398	2017

Systemet kan ikke utføre handlingen. Prøv på nytt senere.

Artikler 1–20

Sitater per år

Duplikatsitater

Sammenslåtte sitater

Legg til medforfattereMedforfattere

Følg

Sitert av

Medforfattere